Procter & Gamble Hosts Global Olympians Justine & Chloe Dufour-Lapointe, Michelle Kwan, Elana Meyers Taylor and Katarzyna Bachleda-Curuś to Discuss Gender Bias
As part of the Olympic Winter Games PyeongChang 2018, Procter & Gamble (NYSE: PG), a Worldwide Olympic Partner, today hosted a panel discussion on gender equality. As part of “Love Over Bias,” the latest installment of P&G’s award-winning “Thank You, Mom” campaign, a panel of decorated female Olympians discussed their own journeys to the global stage. The discussion included the role of their moms, mentorship and support from other women, as well as their hopes for what the current global movement for gender equality will mean for future generations of female athletes.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180213005989/en/
P&G athletes join together for an important discussion about not letting gender become an obstacle to achieving their dreams in a panel hosted by Olympian and retired figure skater Michelle Kwan at the P&G Family Home during the Olympic Winter Games PyeongChang 2018. (Photo: Business Wire)
With opening remarks from Anita DeFrantz, Olympic medalist, the first female Vice President of the IOC Executive Board and a tireless advocate for gender equality in sport, the panel was comprised of:
- Michelle Kwan – Olympic medalist and world champion and the most decorated U.S. figure skater who now serves as a global advocate for her sport and women in business
- Elana Meyers Taylor – 2012 & 2014 Olympic medalist who was one of the first women to pilot a mixed gender, four-man bobsled and has defied stereotypes in her sport
- Katarzyna Bachleda-Curuś – Polish speed skating record holder, two-time Olympic medalist competing in her fifth Olympic Winter Games and proud mom of two daughters
- Justine & Chloe Dufour-Lapointe – Canadian mogul skiers who both medaled at the Olympic Winter Games Sochi 2014. Justine won a silver medal in PyeongChang.
“It’s an exciting time to be a female athlete,” said Elana Meyers Taylor. “There’s this incredible change we’re seeing across all facets of global culture—politics, entertainment, business and of course sport. I’m extremely fortunate that I had fantastic female mentors, including my mom, who helped me overcome any adversity I faced as a female competing in mixed gender bobsled events. I always believed that if I couldn’t do something, my mom would be the one to tell me, and she never did, so I didn’t set limitations for myself and I hope that attitude will inspire other women to define their own potential.”
“I’m proud to partner with P&G today to support the Love Over Bias campaign and participate in a discussion about gender equality,” said Justine Dufour-Lapointe. “I wouldn’t be here without the support and mentorship from other women, including my sisters and my strong and inspiring mom. Together, we can help shape the future for female athletes.”
The discussion also included a screening of P&G Korea’s “Thank You, Mom” video with decorated speed skater Sangwha Lee as well as P&G’s celebrated “Love Over Bias” film, which celebrates a mom’s role as her child’s first and greatest advocate, the one who sees her child’s potential regardless of how others see them. The hope is that this film will help bring people together to talk openly about bias, its role in limiting human potential and the need to see beyond the things that divide us to the common things that can bring us together.
“At P&G, we aspire to create a better world for everyone -- a world free from bias, with equal representation, equal voices and equal opportunity,” said Phil Duncan, Global Design Officer. “The campaign is part of a company-wide effort to spark conversations about important matters, such as gender bias. This has been a longstanding journey for P&G, which includes other campaigns such as Ariel Share the Load, Always Like a Girl , SK-II Marriage Market Takeover, and Secret’s Ladies’ Room Stress Test.”
Share #LoveOverBias and go to www.LoveOverBias.com to view the film and learn more these and other athletes.
About P&G’s Olympic Games Program:
Around the world P&G brands including Always®, Gillette®, Pantene®, Head & Shoulders®, Tide®, Bounty® and Downy® will be executing Olympic Games campaigns through a variety of media channels and in-store. P&G brands are committed to giving moms the best, each and every day. Not just moms of Olympians, but all moms, all around the world. As a Worldwide Olympic Partner, when P&G brands like Tide, Gillette and Pampers partner with athletes on their Olympic Games journey, P&G also recognizes the mom who supported them every step of the way.
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.
Procter & Gamble
Ivanette Bonilla, 513–725–5131
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45 | Tiedote
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10 | Tiedote
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30 | Tiedote
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 20:37 | Tiedote
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10 | Tiedote
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme